Companies pair up to take Rett Syndrome program into clinic

20 July 2017

AMO Pharma and Numedicus have teamed up to advance the development of a glutamate AMO-04 and related compounds for the treatment of Rett Syndrome and certain breathing disorders.

The privately-held firms have agreed a development and license agreement to take forward the glutamate modulator in these areas in an undisclosed deal.

Michael Snape, chief executive of AMO Pharma, said: “The development and licensing agreement for AMO-04 and related compounds reflects our commitment to building our pipeline with additional promising investigational therapies to treat rare diseases with significant areas of unmet need.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK